Tumor-associated endothelial cell surface

The tumor-associated endothelial cell surface is a descriptive term for the collective set of proteins and receptors preferentially expressed on the endothelial cells of tumor-infiltrating blood vessels. Unlike normal endothelial cells, tumor-associated endothelial cells (TECs) express a unique molecular signature known as tumor endothelial markers (TEMs), which include molecules such as TEM1 (Endosialin), TEM8 (Anthrax toxin receptor 1), and Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). These surface molecules serve as critical therapeutic targets for anti-angiogenic agents, vascular disrupting agents, and targeted delivery systems like antibody-drug conjugates (ADCs) or CAR-T cells. Targeting the TEC surface aims to starve the tumor of nutrients, disrupt its blood supply, or directly eliminate the cells supporting the tumor microenvironment. Clinical applications include the use of monoclonal antibodies like ramucirumab, which targets VEGFR2, and experimental agents like ontuxizumab, which targets TEM1. By exploiting the phenotypic differences between tumor and normal vasculature, these therapies aim to minimize systemic toxicity while maximizing anti-tumor efficacy.

Other names

Tumor endothelial markersTEMsTumor-associated endothelial cell markersTumor vasculature surface antigensTEC surface markers

Binding to specific surface receptors or antigens on tumor-associated endothelial cells to inhibit pro-angiogenic signaling pathways, induce antibody-dependent cellular cytotoxicity (ADCC), or deliver cytotoxic payloads directly to the tumor vasculature.